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Abstract
Background: Cardiovascular effects of glucose-lowering agents are of increasing interest. Our aim was to assess
the effects of the glucagon-like peptide-1 receptor agonist exenatide on heart rate (HR) and blood pressure (BP) in
subjects with type 2 diabetes mellitus (T2DM).
Methods: In this double-blind, placebo-controlled trial, subjects with T2DM on metformin and/or a
thiazolidinedione were randomized to receive exenatide (5 μg for 4 weeks followed by 10 μg) or placebo BID for
12 weeks. Heart rate and BP were assessed with 24-hour ambulatory BP monitoring. The primary measure was
change from baseline in mean 24-hour HR.
Results: Fifty-four subjects (28 exenatide, 26 placebo) were randomized and comprised the intent-to-treat
population. Baseline values (exenatide and placebo) were (mean ± SE) 74.4 ± 2.1 and 74.5 ± 1.9 beats/minute for
HR, 126.4 ± 3.2 and 119.9 ± 2.8 mm Hg for systolic BP (SBP), and 75.2 ± 2.1 and 70.5 ± 2.0 mm Hg for diastolic BP
(DBP). At 12 weeks, no significant change from baseline in 24-hour HR was observed with exenatide or placebo (LS
mean ± SE, 2.1 ± 1.4 versus -0.7 ± 1.4 beats/minute, respectively; between treatments, p = 0.16). Exenatide therapy
was associated with trends toward lower 24-hour, daytime, and nighttime SBP; changes in DBP were similar
between groups. No changes in daytime or nighttime rate pressure product were observed. With exenatide, body
weight decreased from baseline by -1.8 ± 0.4 kg (p < 0.0001; treatment difference -1.5 ± 0.6 kg, p < 0.05). The
most frequently reported adverse event with exenatide was mild to moderate nausea.
Conclusions: Exenatide demonstrated no clinically meaningful effects on HR over 12 weeks of treatment in
subjects with T2DM. The observed trends toward lower SBP with exenatide warrant future investigation.
Trial registration: NCT00516074
Background
Glucagon-like peptide-1 (GLP-1), an incretin hormone,
plays a key role in glucose homeostasis [1]. Wide phy-
siological distribution of the GLP-1 receptor suggests
multiple mechanisms of metabolic control, both cen-
trally and through peripheral neurohumoral pathways.
Seminal studies in rodent models demonstrate central
regulation of GLP-1 receptor activation resulting in
dose-dependent increases in heart rate (HR) and blood
pressure (BP) [2,3], while other studies suggest periph-
eral anti-hypertensive effects [4,5]. In higher-animal
models and human studies, few chronotropic and hyper-
tensive effects have been observed [6-16]; however, little
is understood about the cardiovascular effects of GLP-1
receptor activation in humans.
Exenatide is a GLP-1 receptor agonist approved for
the treatment of type 2 diabetes mellitus (T2DM) [17]
and has been associated with improvements in systolic
BP (SBP) in long-term clinical trials [18-22]. In shorter-
term trials, clinical pharmacology studies demonstrated * Correspondence: jkmalone@lilly.com
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characterized. In the present study, we assessed effects
of exenatide on HR and BP over 12 weeks, with the use
of 24-hour BP monitoring, in relatively normotensive
subjects with T2DM.
Methods
Subjects
Subjects with T2DM moderately well controlled with
metformin, a thiazolidinedione, or metformin plus a
thiazolidinedione were recruited from 5 centers in
Canada and the Netherlands. Entry criteria included 18
to 75 years of age, stable metformin dose for 30 days or
thiazolidinedione for 120 days, body mass index >25
and <40 kg/m
2, hemoglobin A1c between 6.5 and 9.5%,
a n ds t a b l eb o d yw e i g h t( ≤ 10% variation for 3 months).
Stable antihypertensive regimens were maintained at
least 6 weeks.
Subjects were excluded if they had a history of clini-
cally significant cardiac disease or cardiac disease within
one year, clinically significant arrhythmia, resting HR
<60 or >100 beats/minute, repeated SBP >160 mm Hg
or diastolic BP (DBP) >100 mm Hg, or current treat-
ment with beta blockers.
Study design
In this multicenter, double-blind, placebo-controlled
trial, subjects received subcutaneous placebo injections
during a 1-week placebo lead-in before randomization to
exenatide or placebo BID for 12 weeks. At Week 4, exe-
natide dose was escalated from 5 μgt o1 0μgB I D ,w h i c h
was continued for the remaining 8 weeks. Study medica-
tion was administered within 60 minutes before morning
and evening meals. Metformin and/or thiazolidinedione
or antihypertensive medications remained constant.
Subjects were instructed on the use of the ambulatory
BP monitor (model 90207; SpaceLabs, Inc.; Redmond,
WA). Monitoring was conducted at baseline, before and
after first dose, before and after dose escalation (Week
4), and at Weeks 5, 8, and 12. Subjects activated the
monitor prior to evening dose (before the evening meal)
and deactivated after 25 hours.
In accordance with the Declaration of Helsinki, the
institutional review board approved a common clinical
protocol for each site. All participants gave informed
written consent.
Measures
The primary measure was change in mean 24-hour HR
from baseline to Week 12. Secondary measures included
hourly HR and change from baseline in the following:
24-hour, daytime/nighttime HR, SBP, and DBP; rate
pressure product (product of HR and SBP); mean arter-
ial pressure (arterial BP of single cardiac cycle); hemo-
globin A1c; and body weight. “Nighttime” was defined as
12:00 AM to 6:00 AM.
Statistical analysis
Fifty subjects were to be randomized. Assuming a 24%
dropout rate, 19 subjects per treatment would complete
the trial, providing 90% power to detect a pre-defined
10-beats/minute treatment difference for the primary
measure, assuming a common standard deviation of
9.23 and a two-sided t test at a significance level of 0.05.
The intent-to-treat population was defined as rando-
mized subjects who received at least one dose of study
medication. The per-protocol population was defined as
intent-to-treat subjects with valid Week-12 ambulatory
BP values, no change in antihypertensive medication,
and no violation of inclusion/exclusion or discontinua-
tion criteria.
The primary measure was based on the per-protocol
population (pre-defined) and assessed by an analysis of
covariance model, including treatment and baseline
value of the dependent variable as covariate. Least
squares (LS) means and p-values were derived from the
model to estimate treatment effects. To support the pri-
mary analysis, a mixed model repeated measures analy-
sis was performed for the intent-to-treat population.
Secondary HR measures; hemoglobin A1c;b o d y
weight; and post- hoc analyses of SBP, DBP, rate pres-
sure product, and mean arterial pressure were based on
the intent-to-treat population. Secondary HR measures,
hemoglobin A1c, body weight, rate pressure product,
and mean arterial pressure were assessed by an analysis
of covariance model similar to the primary analysis. SBP
and DBP were assessed by an analysis of variance model.
Adverse events were summarized by frequency and
percentage. Hypoglycemia rate was summarized by
treatment and visit, with Fisher’s exact test for treatment
comparisons.
Results
Subjects
Fifty-four subjects formed the intent-to-treat population,
45 completed the study, and 36 formed the per-protocol
population (Figure 1). Table 1 presents baseline charac-
teristics. No statistically significant differences were
observed between groups in any of the baseline vari-
ables. Patients were mostly overweight and with BP in
the early stage-1 hypertensive range.
Heart rate
No statistically significantc h a n g ef r o mb a s e l i n ei n2 4 -
hour HR was observed at Week 12 in either group. For
exenatide-treated subjects (per-protocol population), LS
mean (± SE) 24-hour HR change from baseline was 1.5
± 1.8 beats/minute (p = 0.41), and for placebo-treated
subjects, change from baseline was -0.01 ± 1.71 beats/
minute (p = 0.99). There was no treatment difference (p
= 0.54). Intent-to-treat results were similar (exenatide,
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Page 2 of 72.1 ± 1.4 beats/minute, p = 0.13; placebo, -0.7 ± 1.4
beats/minute, p = 0.62; between treatments p = 0.16).
Figure 2 shows hourly HR (intent-to-treat). Overall,
exenatide was not associated with significant changes in
mean 24-hour, daytime, or nighttime HR within or
between groups. A statistically non-significant increase
in mean 24-hour HR (approximately 3 beats/minute)
relative to placebo was observed with exenatide treat-
ment at weeks 5 and 8, with lesser increases at other
times. Of note, immediately after dose escalation, exena-
tide was associated with a small, transient increase in LS
mean 24-hour HR change from baseline (3.4 ± 1.6
beats/minute, p < 0.05). However, nearly half the sub-
jects were missing a valid 24-hour HR value at this
time, and results from the mixed models repeated mea-
sures analysis (2.3 ± 1.6 beats/minute, p = 0.16) did not
support a statistically significant increase.
SBP, DBP, rate pressure product, and mean arterial
pressure
Figure 3 shows changes in 24-hour and nocturnal SBP
(intent-to-treat). A statistically non-significant trend in
decreasing mean 24-hour, daytime, and nighttime SBP
(-3.5, -2.9, and -5.6 mm Hg, respectively) was observed
with exenatide treatment relative to placebo after 2
weeks of treatment. The trend to lower nocturnal SBP
was more prevalent for subjects whose baseline values
were >120 mm Hg. No significant changes from baseline
in mean 24-hour, daytime/nighttime DBP were observed
within or between groups. In post-hoc analyses, no sig-
nificant changes in daytime/nighttime rate pressure pro-
duct or mean arterial pressure at Week 12 were
observed within or between groups.
Body weight and hemoglobin A1c
Exenatide reduced mean body weight from baseline by
-1.8 ± 0.4 kg (p < 0.0001) at Week 12, whereas placebo
resulted in no significant change (-0.3 ± 0.4 kg, p =
0.52). Treatment difference was -1.5 ± 0.6 kg (p < 0.05).
There was a -0.3 ± 0.2% reduction in hemoglobin A1c
for exenatide relative to placebo (p = 0.26).
Adverse events
Mild or moderate nausea was the most frequently
reported adverse event in exenatide-treated subjects
(36% of subjects versus 19% for placebo). No episodes of
severe hypoglycemia were reported. Incidence of minor
Figure 1 Patient flow diagram.
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subjects who received exenatide and placebo,
respectively.
Discussion
Cardiovascular effects of T2DM medications are of
increasing relevance. Exenatide improves glucose home-
ostasis through several mechanisms, with associated
weight loss and low hypoglycemia risk. The aim of the
current study was to characterize HR and BP effects of
exenatide versus placebo in mostly overweight subjects
with BP in the early stage-1 hypertensive range and with
T2DM. Exenatide demonstrated no significant effect on
HR or BP in this 12-week trial, although trends toward
decreased SBP were observed.T h e s eo b s e r v a t i o n sa r e
consistent with larger, longer-term trials that did not
show any apparent cardiovascular safety concerns and
suggested some improvement in SBP [18-22].
Glycemic and BP control are additive in improved
outcomes in subjects with T2DM. An analysis of the
United Kingdom Prospective Diabetes Study demon-
strated that any reduction in SBP is likely to reduce the
risk of complications in subjects with T2DM [25,26]. A
10-mm Hg (6.5%) reduction in SBP was associated with
11% reduction in any diabetes-related endpoint, includ-
ing stroke (18%) and myocardial infarction (11%) [25].
In the Hypertension Optimal Treatment study, small
decreases in SBP and DBP across treatment groups were
associated with reduced major cardiovascular events and
cardiovascular mortality in hypertensive subjects with
T2DM [27]. Accordingly, modest decreases in SBP, as in
the present trial, also may have clinical significance, and
further SBP decreases are likely with additional weight
loss. Studies of longer duration of exenatide use have
suggested improved SBP effects [18-22], notably in sub-
jects with abnormally high baseline SBP values [21].
Table 1 baseline subject characteristics
Characteristics at inpatient screening Exenatide
n=2 8
Placebo
n=2 6
Age, years
a 57 ± 11 54 ± 10
Gender, male, n (%) 19 (68) 11 (42)
Race, n (%)
Caucasian 24 (86) 25 (96)
African 2 (7) 0 (0)
East Asian 1 (4) 1 (4)
Hispanic 1 (4) 0 (0)
Weight, kg
a 91.6 ± 15.2 85.9 ± 12.2
BMI, kg/m
2a 29.5 ± 3.4 30.1 ± 3.9
Hemoglobin A1c,%
a 7.5 ± 0.9 7.1 ± 0.7
Duration of diabetes
a 7±4 6±4
HR, beats/minute
a 75.2 ± 12.4 73.7 ± 9.0
SBP, mm Hg
a 139.4 ± 13.9 138.6 ± 18.7
DBP, mm Hg
a 83.1 ± 7.4 80.1 ± 12.2
Vital signs collected by ambulatory BP monitoring
HR, beats/minute
a
24-hour 74.4 ± 11.0 74.5 ± 9.7
Daytime 75.5 ± 12.0 75.4 ± 10.5
Nighttime 71.2 ± 10.5 71.8 ± 11.1
SBP, mm Hg
a
24-hour 126.4 ± 16.6 119.9 ± 14.0
Daytime 128.0 ± 19.4 121.2 ± 14.7
Nighttime 122.0 ± 14.5 116.1 ± 14.8
DBP, mm Hg
a
24-hour 75.2 ± 11.1 70.5 ± 9.9
Daytime 77.0 ± 12.4 72.1 ± 10.6
Nighttime 69.8 ± 11.6 65.8 ± 10.4
aMean ± standard deviation; intent-to-treat population shown; BMI, body mass index; BP, blood pressure; DBP, diastolic BP; HR, heart rate; SBP, systolic BP
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not suggest increased risk of exenatide on cardiovascular
outcomes [28,29].
These data compare well with previous studies in
which GLP-1 receptor activation conferred no effect on
HR [11-16] with slight trends toward decreased BP in
some cases [11,15]. Exceptions were observed in small
cohorts of fasted healthy volunteers [30] and subjects
with T2DM [23] in short-term studies, with small, tran-
sient increases in HR or BP. In the current study, the
trend towards favorable SBP changes is consistent with
larger, longer-term trials. No increase in rate pressure
p r o d u c to rm e a na r t e r i a lp r e s s u r ea te n d p o i n ti nt h i s
study also implied no increase in cardiac work load.
Data suggesting an increase in HR following dose esca-
lation were not supported by a repeated measures analy-
sis and were considered inconclusive. The observed
change in hemoglobin A1c is likely related to the rela-
tively low baseline value and short duration of treat-
ment. Multiple published studies demonstrated the
glucose-lowering effects of exenatide, typically resulting
in 30-60% of subjects achieving hemoglobin A1c of ≤
7.0% when exenatide is added to ongoing therapy [17].
In this trial, the study population of mostly overweight
subjects (mean BMI for exenatide, 29.5 ± 3.4 and for
placebo, 30.1 ± 3.9 kg/m
2)w i t hB Pi nt h ee a r l ys t a g e - 1
hypertensive range does not represent all patients with
T2DM and is a limitation of the study. The trial was
also limited by the sample size which may have been
insufficient for determining statistical significance in
some non-primary results.
Previous trials with exenatide, some of which included
more obese patients and treatment durations over
longer periods of time, resulted in greater weight loss
and greater reductions in BP than those observed in the
present study [17-20]. Though weight reduction
improves hypertension, apparent BP trends observed in
this study are unlikely solely due to weight loss in view
of the treatment period of this duration [31]. Thus, con-
comitant mechanisms associated with BP trends, in
addition to weight loss, seem plausible and are consis-
tent with other findings. In rodents, Golpon et al. [5]
proposed direct dilatory effects on peripheral vascula-
ture. GLP-1 dose- and time-dependently relaxed pul-
monary arterial rings and reduced pulmonary vascular
tone, presumably mediated by nitric oxide and an intact
endothelium. However, other studies also suggest the
possibility of nitric oxide- and endothelium-independent
relaxant effects [32]. In humans, activation of the GLP-1
receptor, also isolated from human coronary artery
Figure 2 Hourly heart rates during 24-hour monitoring. Heart rate values at baseline (A), after first dose (B), after dose escalation (C), and at
Week 12 (D) for the intent-to-treat population are shown.
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Page 5 of 7endothelial cells, resulted in vasodilation of brachial
arteries and improved endothelial dysfunction in sub-
j e c t sw i t hT 2 D Mw i t hc o r o n a r yh e a r td i s e a s e[ 1 4 ] .
These reports suggest direct activation of the GLP-1
receptor in peripheral endothelial tissue, mediating vaso-
dilatory effects, as a possible mechanism.
The findings of this study suggest that 12-week adminis-
tration of exenatide had little effect on HR and showed
some trends of improved BP effects. Larger subsequent
studies should clarify the effect of exenatide on trends in
cardiovascular markers, including weight loss and SBP,
and explore the potential for lowering overall risk.
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